# ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

> **NCT04172259** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 156 (estimated)

## Conditions studied

- Breast Cancer
- Neoadjuvant Chemotherapy

## Interventions

- **DRUG:** Doxorubicin liposome
- **DRUG:** Cyclophosphamide
- **DRUG:** Trastuzumab
- **DRUG:** Docetaxel
- **DRUG:** Epirubicin
- **DRUG:** Pertuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Paclitaxel-albumin

## Key facts

- **NCT ID:** NCT04172259
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-10
- **Primary completion:** 2023-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172259, "ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04172259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*